Skip to main content

Table 2 Summary of the prediction models, their stages of development, the cancer sites covered and study designs

From: Development, validation and effectiveness of diagnostic prediction tools for colorectal cancer in primary care: a systematic review

Prediction model

Number and category of descriptors

Stage of development

Study design

Country

Population

Source

Colorectal cancer

 Bristol-Birmingham equation

8

Symptoms, Test results

External validation

Retrospective Case-control

UK

Derivation cohort: THIN

Validation cohort: CAPER

Marshall 2011 [29]

  

External validation

Prospective cohort

The Netherlands

CEDAR study: Patients referred to endoscopy centres by participating Dutch primary care practices. 2009–2012

Elias 2017 [27]

 Netherlands model

3

Symptoms, Patient demographics

Apparent performance

Prospective cohort

The Netherlands

290 consecutive patients with rectal bleeding presenting to 83 GPs in Limburg (Netherlands) September 1988 to April 1990Predictors: Questionnaires completed by GPs and patients, and laboratory test results.

Fijten 1995 [28]

  

External validation

Prospective cohort

UK

patients referred from primary care with colorectal symptoms over a 3-yr period to the Leighton Hospital, Crewe, Cheshire, UK

Hodder 2005 [40]

  

External validation

Prospective cohort

Netherlands

CEDAR study: Patients referred to endoscopy centres by participating Dutch primary care practices. 2009–2012

Elias 2017 [27]

 Machine learning algorithm

Numerous models are reported

Patient demographics, Symptoms, Medical history, Test results

Apparent performance

Case-control

The Netherlands

anonymised electronic records from two GP database systems from the Utrecht region, Netherlands, between 01 and 07-2006 and 31-12-2011

Kop 2015 [41]; Kop 2016 [32]; Hoogendoorn 2015 [42]

 Danish model

2

Patient demographics

Symptoms

Apparent performance

Prospective cohort

Denmark

Patients presenting to GPs with first episode of rectal bleeding.

Study 1: 750 GPs 1989–1991

Study 2: 450 GPs 1991–1992

Nørrelund 1996 [31]

  

External validation

Prospective cohort

The Netherlands

CEDAR study: Patients referred to endoscopy centres by participating Dutch primary care practices.

2009–2012

Elias 2017 [27]

 Qcancer

6 (females)

7 (males)

Symptoms, Medical history, Test results

Internal validation

open Prospective cohort

UK

QResearch database

Hippisley-Cox 2012c [22]

  

External validation

Prospective cohort

UK

THIN database

Collins 2012 [23]

 RAT (2005)

10

Symptoms, Test results

Apparent performance

Case-control

UK

Patients attending all 21 general practices in Exeter, Devon, UKCases identified from the cancer registry at the Royal Devon and Exeter Hospital

Hamilton 2005 [33]

  

External validation

Prospective cohort

The Netherlands

CEDAR study: Patients referred to endoscopy centres by participating Dutch primary care practices.

2009–2012

Elias 2017 [27]

 RAT (2009)

8

Symptoms, Test results

Apparent performance

Case-control

UK

THIN database

Hamilton 2009 [43]

 RAT (bowel)

10

Symptoms, Test results

Apparent performance

Case-control

UK

GPRD (currently called the CPRD)

Stapley 2017 [35]

Metastatic cancer

 RAT

7

Symptoms, Test results

Apparent performance

Case-control

UK

Patients attending 11 general practices in Devon, UK

Hamilton 2015 [36]

Multiple cancer sites

Qcancer (female)

7 (uterine)

10 (breast, blood)

11 (ovarian, renal)

12 (cervical)

13 (colorectal, gastro-oesophageal)

14 (pancreatic)

15 (lung)

22 (other cancers)

Medical history, Symptoms, Test results, Patient demographics

Internal validation

Open prospective cohort

UK

QResearch database

Hippisley-Cox 2013 [38]

QCancer (male)

3 (testicular)

8 (renal tract)

12 (colorectal)

13 (gastro-oesophageal)

14 (prostate, blood)

15 (pancreatic)

17 (lung)

20 (other cancers)

Medical history, Symptoms, Test results, Patient demographics

Internal validation

Open prospective cohort

UK

QResearch database

Hippisley-Cox 2013b [37]

Muris abdominal complaints model

5

Symptoms

Patient demographics

Test results

Apparent performance

Prospective cohort

The Netherlands

Patients presenting to GPs for new abdominal complaints. 1989

Muris 1995 [30]

(Netherlands)

 

External validation

Prospective cohort

The Netherlands

CEDAR study: Patients referred to endoscopy centres by participating Dutch primary care practices.

2009–2012

Elias 2017 [27]

Abdominal model, Holtedahl and colleagues (2018)

4

Symptoms, Patient demographics

Apparent performance

Prospective cohort

Norway, Denmark, Sweden, Scotland, Belgium, Netherlands

GP records from the participating countries

Holtedahl, 2018 [39]

  1. Abbreviation: RAT(s) Risk assessment tool(s)